


Claims


What is claimed is:

1. The compound



or a salt, solvate, or polymorph thereof.

2. A salt as recited in claim 1, of structural Formula I:



or a polymorph thereof, wherein:


R^- is chosen from Cl^- , Br^- , I^- , HSO_4^- , SO_4^{2-} , NO_3^- , $CH_3SO_3^-$, $PhSO_3^-$, 4-MePh SO_3^- , Naphthalene SO_3^- ;

n is an integer from 0 to 2; and

Y is an optional solvate.

3. The salt as recited in claim 2, wherein the solvate is DMSO.
4. The salt as recited in claim 2, wherein the DMSO is associated with the compound in a 1:1 ratio.
5. The salt as recited in claim 2, wherein R^- is chosen from Cl^- , HSO_4^- , $CH_3SO_3^-$, and 4-MePh SO_3^- .
6. The salt as recited in claim 5, wherein n is 1.
7. The salt as recited in claim 5, wherein Y is absent.
8. The salt as recited in claim 7, wherein R^- is $CH_3SO_3^-$.

9. The salt as recited in claim 8, having one or more x-ray powder diffraction peaks chosen from about 9.2, about 10.8, about 13.8, about 16.7, about 17.3, about 18.4, about 18.7, about 19.9, about 20.6, about 21.4, about 22.1, about 22.3, about 22.6, about 22.9, about 24.1, and about 32.1 degree 2-theta.
10. The salt as recited in claim 7, wherein R⁻ is Cl⁻.
11. The salt as recited in claim 10, having one or more x-ray powder diffraction peaks chosen from about 4.6, about 9.26, about 11.0, about 12.6, about 13.2, about 13.8, about 16.5, about 19.0, about 20.8, about 22.0, about 22.4, about 22.7, about 24.2, about 25.0, and about 33.4 degree 2-theta.
12. The salt as recited in claim 7, wherein R⁻ is 4-MePhSO₃⁻.
13. The salt as recited in claim 12, having one or more x-ray powder diffraction peaks chosen from about 4.5, about 9.0, about 10.3, about 10.5, about 10.7, about 11.1, about 11.7, about 13.6, about 14.3, about 17.1, about 17.3, about 17.6, about 18.5, about 18.9, about 19.0, about 19.2, about 19.8, about 20.1, about 20.4, about 20.8, about 21.4, about 21.8, about 22.4, about 22.6, about 23.4, about 24.3, about 25.1, about 26.0, about 26.3, about 27.2, about 27.4, and about 28.2 degree 2-theta.
14. The solid compound



or a polymorph thereof.

15. The solid compound as recited in claim 14, which is crystalline.
16. Polymorph A of the solid compound as recited in claim 14.
17. Polymorph B of the solid compound as recited in claim 14.
18. Polymorph C of the solid compound as recited in claim 14.
19. Polymorph D of the solid compound as recited in claim 14.
20. The polymorph D as recited in claim 19, having one or more x-ray powder diffraction peaks chosen from about 4.0, about 8.0, about 11.6, about 11.9, about 14.9, about 15.9,

about 17.6, about 19.9, about 20.2, about 22.4, about 23.7, and about 23.9 degrees 2-theta.

21. The Polymorph D as recited in claim 20, which comprises three or more of the peaks.
22. The Polymorph D as recited in claim 20, which comprises five or more of the peaks.
23. The Polymorph D as recited in claim 19, wherein said polymorph displays an endothermic peak in DSC with onset of $197^{\circ}\text{C} \pm 1^{\circ}\text{C}$.
24. The Polymorph D as recited in claim 19, wherein said polymorph is anhydrous.
25. The Polymorph D as recited in claim 19, wherein said polymorph displays weight loss in DSC of less than 1% from 30°C to 200°C
26. A composition comprising the compound of claim 14, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.